Posoleucel, an allogeneic, off-the-shelf multivirus-specific T-cell therapy, for the treatment of refractory viral infections in the post-HCT setting

Authors

Thomas Pfeiffer, Washington University School of Medicine in St. Louis
et al.

Journal

Clinical cancer research

Publication Date

1-17-2023

Volume

29

Issue

2

First Page

324

Last Page

330

Document Type

Open Access Publication

DOI

10.1158/1078-0432.CCR-22-2415

Rights and Permissions

Pfeiffer T, Tzannou I, Wu M, Ramos C, Sasa G, Martinez C, Lulla P, Krance RA, Scherer L, Ruderfer D, Naik S, Bocchini C, Fraser IP, Patel B, Ward D, Wang T, Heslop HE, Leen AM, Omer B. Posoleucel, an Allogeneic, Off-the-Shelf Multivirus-Specific T-Cell Therapy, for the Treatment of Refractory Viral Infections in the Post-HCT Setting. Clin Cancer Res. 2023 Jan 17;29(2):324-330. doi: 10.1158/1078-0432.CCR-22-2415. This open access article is distributed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0) license.

Recommended Citation

Pfeiffer, Thomas and et al., "Posoleucel, an allogeneic, off-the-shelf multivirus-specific T-cell therapy, for the treatment of refractory viral infections in the post-HCT setting." Clinical cancer research. 29, 2. 324 - 330. (2023).
https://digitalcommons.wustl.edu/oa_4/1182